Avalo Therapeutics Inc. (AVTX)
6.69
-0.62 (-8.48%)
At close: Mar 03, 2025, 3:59 PM
6.70
0.15%
After-hours: Mar 03, 2025, 04:00 PM EST
Avalo Therapeutics Income Statement
| Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
| Revenue | 1.92M | 18.05M | 5.4M | 6.7M | 6.75M | 18.33M | 27.81M | 1.15M | n/a | n/a | n/a | 82.76K |
| Cost of Revenue | 1.28M | 3.43M | 1.49M | 300K | 11.63M | 7.48M | 635.65K | 8.24M | 23.51K | 9.5M | n/a | 8.48M |
| Gross Profit | 640K | 14.62M | 3.91M | 6.4M | -4.88M | 10.85M | 27.18M | -7.09M | -23.51K | -9.5M | n/a | -8.39M |
| Operating Income | -23.44M | -37.44M | -82.13M | -26.95M | -17.39M | -39.31M | 13.89M | -16.08M | -11.01M | -17.12M | -12.93M | -10.49M |
| Interest Income | n/a | 4.17M | 2.39M | 49K | 121.33K | n/a | n/a | n/a | n/a | n/a | n/a | 1.35K |
| Pretax Income | -31.53M | -41.63M | -84.55M | -67.18M | -15.99M | -40.09M | 13.84M | -16.47M | -10.49M | -16.06M | -13.05M | -10.49M |
| Net Income | -31.54M | -41.66M | -84.35M | -64.38M | -16.27M | -40.05M | 11.87M | -16.47M | -10.49M | -16.06M | -13.05M | -10.49M |
| Selling & General & Admin | 10.3M | 20.71M | 24.66M | 19.76M | 11.61M | 19.2M | 8.91M | 7.08M | 4.42M | 4.88M | 4.02M | 2.1M |
| Research & Development | 13.78M | 31.31M | 59.84M | 32.19M | 11.76M | 5.79M | 4.37M | 10.15M | 6.59M | 12.24M | 8.91M | 8.48M |
| Other Expenses | -23.44M | 38K | 1.55M | 1.74M | 1.34M | 13.66K | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Expenses | 640K | 52.06M | 86.04M | 53.69M | 24.71M | 29.52M | 13.29M | 17.23M | 11.01M | 17.12M | 12.93M | 2.1M |
| Interest Expense | 3.42M | 4.17M | 2.39M | n/a | n/a | n/a | n/a | n/a | 793.21K | 1.21M | 10.55K | n/a |
| Selling & Marketing Expenses | 33K | 76K | 2.83M | 2.34M | 1.48M | 8.52M | 973.35K | n/a | n/a | n/a | n/a | n/a |
| Cost & Expenses | 25.37M | 55.49M | 87.53M | 53.99M | 24.14M | 37M | 13.92M | 17.23M | 11.01M | 17.12M | 12.93M | 10.57M |
| Income Tax | 14K | 28K | -196K | -2.79M | 280K | -33.91K | 1.97M | 364.14K | -543.51K | -1.06M | 110.56K | n/a |
| Shares Outstanding (Basic) | 277.73K | 39.2K | 36.19K | 25.51K | 19.85K | 12.07K | 6.39K | 3.07K | 772.92 | n/a | n/a | 52.51K |
| Shares Outstanding (Diluted) | 277.73K | 39.2K | 36.19K | 25.51K | 19.85K | 12.07K | 6.51K | 3.07K | 772.92 | n/a | n/a | 52.51K |
| EPS (Basic) | -113.58 | -1.06K | -2.33K | -2.52K | -819.74 | -3.32K | 1.21K | -5.37K | -13.57K | n/a | n/a | -199.77 |
| EPS (Diluted) | -113.58 | -1.06K | -2.33K | -2.52K | -819.74 | -3.32K | 1.21K | -5.37K | -13.57K | n/a | n/a | -199.77 |
| EBITDA | -27.95M | -37.29M | -80.5M | -45.45M | -17.36M | -13.07M | 14.35M | -16.05M | -10.46M | -17.09M | -12.91M | -10.48M |
| Depreciation & Amortization | 158K | 166K | 1.66M | 1.84M | 1.46M | 1.85M | 425.48K | 26.86K | 23.51K | 28.94K | 20.03K | 15K |